MedTech News
.................... by Andrew Celentano

A step toward lab‑grown sperm: Scientists turn stem cells into early sperm cells in a mini‑testis
About 9% of men of reproductive age in the United States experience fertility problems.

HoneyNaps Receives U.S. FDA 510(k) Clearance for SOMNUM V3.0 for AI-Based Sleep-Disordered Breathing Analysis
BOSTON, July 16, 2026 /PRNewswire/ — HoneyNaps, an AI-based sleep medicine company, today announced that SOMNUM V3.0, its AI diagnosis software for polysomnography (PSG) analysis, has received U.S. Food and Drug Administration (FDA) clearance under clearance number K253390.

ElectroWire Medical gains FDA clearance for transseptal puncture system
The LightningWire system is designed to support transseptal access in procedures such as atrial fibrillation ablation, left atrial appendage closure and transcatheter mitral interventions.

Simple Urine Test Could Transform Early Detection of Chronic Kidney Disease, Lancet Series Finds
The disease is projected to become the fifth leading cause of death by 2040 if diagnosis and treatment rates do not improve

Researchers link gut microbe to cancer-fighting immune response
Lincoln researchers are the first to show that metabolites produced by certain gut bacteria can positively affect the body’s immune response to cancer.

Maestros of healing: How ‘good’ immune cells help regenerate spinal cord injuries
Humans cannot fully heal spinal cord injuries. When the spinal cord is damaged, the body’s immune system often spirals into chaos. This overwhelming inflammatory response creates permanent scar tissue that stops nerve cells from ever repairing themselves or their connections. Zebrafish, however, have mastered the biological art of managing this cellular chaos to completely heal spinal cord damage.

Shape-shifting drug hits tumors in multiple ways, improves outcomes in mice
Modern anticancer medications that combine tumor-fighting drugs with proteins that specifically target cancer cells are a relatively new class of drugs, often given to patients for whom standard chemotherapy has not worked. The drugs are precise but can attack only one type of target in a cancer cell at a time. This limits their effectiveness against tumors containing multiple types of targets, which becomes more likely as cancer progresses or tumors become resistant to conventional therapies.

Drug candidate could help L-dopa work better for patients with Parkinson’s
The most effective treatment for Parkinson’s remains L-dopa, also called levodopa, a medication that can dramatically improve movement and quality of life. But the relief often comes with a caveat: Over time, the drug’s benefits can become less reliable, and it can cause erratic, involuntary movements known as dyskinesia.